These extra-glycaemic effects are particularly advantageous given the high incidence of obesity and hypertension among patients with type 2 diabetes, and contrasts with other diabetes drug classes including sulphonylureas and insulin [26,35]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.